Corpus ID: 39413621

FarmacologÌa de los agentes antiagregantes plaquetarios

  title={Farmacolog{\`I}a de los agentes antiagregantes plaquetarios},
  author={V. Molina and L. Arruzazabala and D. Carbajal and R. M{\'a}s},
The platelets have been implicated in the pathogenesis of arterial thrombotic disorders. For this reason, the modifications of platelet function play an impo... 
Niveles del factor de crecimiento derivado de plaquetas en el plasma rico en plaquetas antes y despues de antiagregantes plaquetarios (PDGF levels in platelet-rich plasma before and after anti platelets drugs)
PDGF is one of the most potent mitogen for connective tissue, its secretion appears to be particularly important when the source is Platelet Rich Plasma (PRP), hence the latter leading role in tissueExpand
PDGF and VEGF Levels in Platelet-Rich Plasma
It was noted that after administration of antiplatelet drugs PDGFBB and VEGF values decreased statistically significantly, especially for the group of Clopidogrel. Expand
Stevia rebaudiana Bertoni, source of a high-potency natural sweetener: A comprehensive review on the biochemical, nutritional and functional aspects.
Stevia rebaudiana Bertoni, an ancient perennial shrub of South America, produces diterpene glycosides that are low calorie sweeteners, about 300 times sweeter than saccharose, which are thought to possess antioxidant, antimicrobial and antifungal activity. Expand


Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
This study was undertaken to evaluate the efficacy, safety, and tolerability of policosanol, a new cholesterol‐lowering drug, in patients with type II hypercholesterolemia and additional coronaryExpand
Pharmacology of thromboxane synthetase inhibitors.
Although any clinical utility of thromboxane synthetase inhibition remains to be demonstrated, it may be useful in conditions where vasoconstriction or vasospasm are involved, particularly where platelet activation is a contributing factor. Expand
NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus.
The implementation of evidence-based guidelines was considered likely to be able to effect a substantial reduction in toxicity without significant loss of overall therapeutic benefit. Expand
Thrombotic thrombocytopenic purpura associated with clopidogrel.
Thrombotic thrombocytopenic purpura can occur after the initiation of clopidogrel therapy, often within the first two weeks of treatment, and Physicians should be aware of the possibility of this syndrome when initiating clopIDogrel treatment. Expand
[Abciximab-induced thrombopenia during treatment of acute coronary syndromes by angioplasty].
  • P. Pinton
  • Medicine
  • Annales de cardiologie et d'angeiologie
  • 1998
All patients treated with abciximab must be monitored by platelet count, 2 to 4 hours after the bolus administration, then 12 and 24 hours later, in order to eliminate pseudothrombocytopenia and a differential diagnosis. Expand
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.
Why these drugs can be more efficacious than traditional antiplatelet agents is explained here and the available experimental studies involving these drugs are reviewed. Expand
Antiplatelet and antithrombotic effect of D-003.
The time-course effects of D-003 on platelet aggregation, arterial thrombus formation, and bleeding time showed no effect 0.5 h after dosing, and maximal effects exhibited 1-2 h after treatment, whereas no significant effects were found 4H after treatment. Expand
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A.
The efficacy of clopidogrel was increased in animals pretreated with 3-methylcholanthrene and beta-naphthoflavone, indicating that the cytochrome P450-1A subfamily pathway was mainly involved in the activating metabolism of clobidog rel, and the use of specific antibodies directed against the various cyto Chrome P450 subfamilies ascertained this observation. Expand
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Inhibitors of GP IIb-IIIa complexes, including c7E3, block the final step of the platelet aggregation process as used by all physiologic agonists and are proving powerful therapeutic agents. Expand
Effect of policosanol on experimental thrombosis models.
Policosanol significantly decreased the thrombus weight and was able to reduce rectal temperature variation induced by arterial thrombosis, and increased 6-keto-PGF1 alpha serum levels in rats at the same dose. Expand